Biosignaling

Overview: Why Cells Need Rules — and What Happens When They Break Them

Every cell makes a constant decision: grow and divide, stay put and function, or die. Biosignaling is the communication network behind these decisions. Two high-yield topics sit at opposite ends of it: oncogenes, runaway "go" signals that drive cancer, and apoptosis, the orchestrated cell-death program that keeps tissues healthy. Both corrupt or co-opt the normal signaling machinery, so start there.

Priority labels: Must know = cold; Know the logic = mechanism not names; Passage-level = recognize, don't memorize; Optional = skippable.

---

Normal Signal Transduction: The Foundation

Know the logic

A typical growth-signaling cascade runs as a chain:

1. A ligand (growth factor, e.g. EGF) binds a transmembrane receptor tyrosine kinase (RTK).
2. Receptor dimerization → autophosphorylation of intracellular tyrosines.
3. Adaptor docking activates RAS, a membrane GTPase.
4. RAS-GTP drives the MAPK cascade (RAF → MEK → ERK) → transcription of proliferative genes.

Passage-level

Two other downstream pathways worth recognizing: the PI3K–AKT axis (survival/growth via mTOR) and JAK–STAT (immune/hematopoietic signaling).

The key takeaway: any step in these cascades, if mutated or overexpressed to be permanently "on," can become oncogenic.

Quick check: Why would a receptor tyrosine kinase that cannot be dephosphorylated be cancer-promoting?

Answer: It stays constitutively active, continuously signaling "divide" even without ligand — mimicking permanent growth-factor stimulation, a classic oncogenic mechanism.

---

Proto-Oncogenes and Oncogenes

What Is a Proto-Oncogene?

Must know

A proto-oncogene is a normal accelerator pedal — it encodes growth-signaling proteins (growth factors, receptors, signal transducers, transcription factors). A mutation converts it into an oncogene, jamming the accelerator to the floor.

Oncogenes act as dominant gain-of-function mutations — one mutant allele is enough. This contrasts sharply with tumor suppressors (below).

Mechanisms of Oncogene Activation

Know the logic

Three routes turn a proto-oncogene into an oncogene:

• Point mutation → constitutively active protein (classic: RAS, locked active).
• Gene amplification → overexpression (e.g., a receptor amplified so it signals without ligand).
• Chromosomal translocation → gene placed next to a strong promoter, or a fusion oncoprotein.

Key Oncogenes to Know Conceptually

Must know

RAS is the canonical example. Wild-type RAS is a GTPase that hydrolyzes GTP → GDP (aided by GAP) to turn itself off. An oncogenic mutation impairs hydrolysis, locking RAS in the active GTP-bound state → perpetual proliferation signal.

MYC is a transcription factor that broadly upregulates cell-cycle/growth genes; overexpression can push cells into S-phase without external signals.

Tumor Suppressor Genes: The Brakes

Must know

The MCAT tests oncogenes in contrast to tumor suppressors, so you need both sides. Tumor suppressors restrain the cell cycle, promote apoptosis, or repair DNA. They follow the two-hit hypothesis: both alleles must be inactivated (loss of function), making them recessive at the cellular level.

Rb: active (hypophosphorylated) Rb sequesters the transcription factor E2F, blocking S-phase entry. Cyclin–CDK phosphorylates Rb → E2F released → S-phase. Rb loss → unchecked E2F → uncontrolled proliferation.

p53 ("guardian of the genome"): a transcription factor activated by DNA damage, hypoxia, or oncogenic stress. It triggers cell-cycle arrest (via p21), DNA repair, or apoptosis if damage is irreparable. It is the most commonly mutated tumor suppressor in human cancer; its loss lets damaged cells keep dividing.

Quick check: A patient has familial retinoblastoma: one defective Rb allele inherited, one normal. How many additional mutational "hits" are needed in a retinal cell to develop a tumor?

Answer: Just one — the second allele must be inactivated. Familial retinoblastoma is highly penetrant because the first hit is already present in every cell.

---

Additional Hallmarks of Cancer Relevant to Biosignaling

Passage-level

Recognize these signaling-related cancer behaviors; don't memorize the list cold.

• Loss of contact inhibition: normal cells stop dividing when crowded; cancer cells pile up (form foci).
• Telomerase reactivation: cancer cells re-express telomerase to extend telomeres → effective immortality.
• Angiogenesis: tumors secrete VEGF to recruit new blood vessels.
• Autocrine signaling: a cell secretes its own growth factor and expresses the receptor, creating a self-sustaining loop that bypasses normal external signals.

Quick check: A cancer cell constitutively secretes EGF and overexpresses EGFR. What type of signaling is this, and how does it help the tumor?

Answer: Autocrine signaling. The cell stimulates its own EGFR without external input, making proliferation independent of tissue context and normal growth-factor gradients.

---

Apoptosis

The Big Picture: Why Controlled Death Matters

Must know

Apoptosis is programmed cell death — essential for development (sculpting fingers), immune function (deleting autoreactive T-cells), and tumor suppression (killing irreparably damaged cells). It is distinct from necrosis, the uncontrolled, inflammatory death from trauma or toxins.

Cellular hallmarks of apoptosis: cell shrinkage and chromatin condensation; membrane blebbing; fragmentation into apoptotic bodies (cleanly phagocytosed, no inflammation); internucleosomal DNA fragmentation (gel "ladder"); phosphatidylserine flip to the outer leaflet ("eat me" signal).

The molecular executors are the caspases — proteases made as inactive zymogens, switched on by cleavage. Initiator caspases detect the death signal and activate executioner caspases, which dismantle the cell. Two routes reach caspase activation: an intrinsic (mitochondrial) and an extrinsic (death-receptor) pathway.

The Intrinsic (Mitochondrial) Pathway

Know the logic

Triggered by internal stress (DNA damage, hypoxia, oxidative or oncogenic stress). The decision point is the mitochondrial outer membrane, set by the balance of anti-apoptotic vs. pro-apoptotic Bcl-2-family proteins. When pro-apoptotic signals win, the membrane is permeabilized and cytochrome c is released, assembling with APAF-1 into the apoptosome, which activates caspases:

$\text{Stress} \rightarrow \text{mitochondrial pore} \rightarrow \text{Cytochrome } c \text{ release} \rightarrow \text{Apoptosome (APAF-1)} \rightarrow \text{caspase activation}$

The Extrinsic (Death Receptor) Pathway

Know the logic

Triggered by external death ligands binding death receptors (classic pair: Fas ligand / Fas, used by cytotoxic T-cells). Ligand binding clusters receptors → adaptor recruitment → initiator caspase → executioner caspases. This pathway can also amplify the intrinsic pathway.

p53 and Apoptosis: The Connecting Thread

Know the logic

p53 links oncogene biology to apoptosis. When an oncogene like RAS is activated, the resulting stress stabilizes p53, which either arrests the cell for repair or upregulates pro-apoptotic proteins to drive death. This is why p53 loss is catastrophic: damaged cells that should die instead survive and proliferate.

Too Little Apoptosis Can Also Cause Cancer

Must know

An overexpressed anti-apoptotic regulator behaves like an oncogene: survival signals stuck "on" let cells that should die accumulate. Cancer can arise from insufficient apoptosis, not just excess proliferation.

Quick check: How can a mutation that does not increase proliferation rate still promote cancer?

Answer: By blocking apoptosis. Overactive anti-apoptotic signaling lets damaged or unwanted cells survive and accumulate; over time this long-lived population acquires further mutations — so deregulated cell death contributes to cancer just as deregulated cell division does.

---

Integrating Oncogenes and Apoptosis: The Cancer Perspective

Know the logic

Cancer requires deregulation of multiple safeguards — the multistep model of carcinogenesis:

1. Oncogene activation (e.g., RAS) → proliferative signal.
2. Oncogenic stress normally triggers p53 → apoptosis/senescence (an anti-tumor defense).
3. p53 loss → cells with active RAS now survive.
4. Additional hits (Rb loss, telomerase, angiogenesis) → malignant tumor.

This is why cancer takes years and tumors accumulate many mutations — each is a failed safeguard.

Quick check: Why does RAS mutation alone rarely cause cancer in experimental models, but RAS + p53 loss frequently does?

Answer: Oncogenic RAS triggers an oncogenic-stress response that stabilizes p53 and pushes cells into apoptosis or senescence — an intrinsic anti-tumor brake. Without p53, RAS-active cells escape this brake and proliferate. This is why multiple mutations are typically required for full transformation.

---

Common Confusions & Tricks

Oncogenes are dominant; tumor suppressor loss is recessive. One bad oncogene copy is enough (gain of function); you must knock out both tumor-suppressor copies (loss of function). Oncogene = broken "on switch" (one is enough); tumor suppressor = brakes (lose both).

Anti-apoptotic regulators can be oncogenic. Not every apoptosis-related protein promotes death. Anti-apoptotic Bcl-2-family members prevent apoptosis; overexpressed, cells live too long and cancer is favored. Read which side of the balance a protein is on.

Cytochrome c has two lives. In a healthy cell it shuttles electrons in the ETC (between Complex III and IV). Released into the cytoplasm during apoptosis, it triggers the apoptosome. Recognize which context a passage intends.

Initiator vs. executioner caspases: initiators start the cascade (one per pathway); executioners are activated downstream and dismantle the cell. Both pathways converge on executioner caspases.

Apoptosis ≠ Necrosis. Necrosis is passive, inflammatory, swelling/lysis with content release. Apoptosis is active (ATP-dependent), non-inflammatory, neat apoptotic bodies, cell shrinkage. Inflamed tissue → necrosis; shrunken cells with condensed chromatin quietly cleared by macrophages → apoptosis.

RAS inactivates itself by hydrolyzing GTP → GDP. GAP accelerates this; oncogenic mutations impair it, so RAS sticks "on." GDP-bound = inactive; GTP-bound = active.

Proto-oncogene → oncogene is not a two-hit event. The Knudson two-hit model applies only to tumor suppressors.

---

Key Relationships at a Glance

Note: This is a mechanistic signaling topic — no quantitative formulas to memorize. The relationships below summarize the cause-and-effect chains the MCAT tests.

Relationship	What it means
$\text{Proto-oncogene} \xrightarrow{\text{mutation / amplification / translocation}} \text{Oncogene}$	One mutant allele is sufficient (dominant, gain-of-function); drives proliferation
$\ce{RAS{-}GDP <=> RAS{-}GTP}$ (GTP-bound = active)	A molecular switch; oncogenic RAS can't hydrolyze GTP, so it is stuck "on"
$\text{Rb} \xrightarrow{\text{phosphorylation}} \text{Rb-P (inactive)}$	Phosphorylation releases E2F → S-phase entry; loss of Rb removes the brake
$\text{p53} \xrightarrow{\text{DNA damage}} \text{cell-cycle arrest, repair, or apoptosis}$	"Guardian of the genome"; its loss lets damaged cells survive and divide
anti-apoptotic vs. pro-apoptotic balance	Sets whether the mitochondrial pathway fires; tilted toward survival → cancer